News

CDER: Avastin Breast Cancer Claim Undermines Approval Process


 

FROM THE CENTER FOR DRUG EVALUATION AND RESEARCH

Genentech does not explain how it would enroll patients in a new, blinded, controlled trial of Avastin in combination with paclitaxel if this remains a labeled use, CDER says. Furthermore, such a study would likely take many years to complete.

"Rather than serving as a basis to ‘maintain’ approval, which is not part of the accelerated approval program, the new research proposed by Genentech, if completed favorably, could be used to support a new sBLA [Supplemental Biologics License Application] requesting an MBC indication."

Chemotherapy Partner Hypothesis Does Not Hold Water

Genentech has hypothesized that chemotherapy partners that provide for prolonged combined exposure with Avastin may result in the strongest treatment effect. Yet this hypothesis has not been substantiated by either clinical or nonclinical evidence, CDER says.

"To support this argument, CDER expects that there should be some proven scientific basis for substantial differences, such as evidence of drug interactions or synergistic/overlapping toxicity between Avastin and other chemotherapy drugs. There is none," CDER says. Evidence submitted to date, such as population pharmacokinetic analyses, suggest no unique interactions between Avastin and any of the chemotherapy agents administered in the trials.

"In the absence of a scientifically supported basis for chemotherapy-specific interactions the more likely explanation for the failure of the clinical trials to verify the results of the E2100 trial is that the magnitude of the PFS treatment effect observed in E2100 is an outlier."

Genentech’s argument on the importance of chemotherapy partner used also runs contrary to its prior position, CDER says, noting that the company initially sought broad approval of Avastin in combination with all taxane-based chemotherapies based solely on the E2100 data.

No One Is Moving Goal Posts at CDER

CDER further disputes Genentech’s argument that it has changed its approval standards for MBC treatments. The regulator consistently maintained in conversations with Genentech that the adequacy of PFS as an approval end point would depend upon the overall dataset and the magnitude of benefit, it says.

"CDER has not in any way sought to ‘move the goal posts,’ " the filing states. "CDER has not determined that a set magnitude of PFS improvement is needed to support an MBC indication; however, CDER has determined that the magnitude of PFS improvement shown in Avastin’s MBC post-approval studies, and shown in the totality of the relevant data, is so small that the risk-benefit balance is unfavorable."

This coverage is provided courtesy of "The Pink Sheet." "The Pink Sheet" and Internal Medicine News Digital Network are both owned by Elsevier.

Pages

Recommended Reading

Trastuzumab Benefit Persists at 4 Years in HER2-Positive Breast Cancer
Breast Cancer ICYMI
FDA Grants Hearing on Withdrawal of Bevacizumab Approval
Breast Cancer ICYMI
Eribulin Extends Survival of Women With Heavily Pretreated Breast Cancer
Breast Cancer ICYMI
Techniques Compared for Breast Tumor Detection
Breast Cancer ICYMI
Clinical Trial Participation Tied to Improved Breast Cancer Outcomes
Breast Cancer ICYMI
Bone Micrometastases Show No Survival Impact in Early Breast Cancer
Breast Cancer ICYMI
NCCN Breast Guidelines Stand by Bevacizumab
Breast Cancer ICYMI
Sequencing Reveals MAP3K1 Mutation in Luminal-Type Breast Cancer
Breast Cancer ICYMI
Radioactive Seeds Guide Surgeons to Nonpalpable Breast Lesions
Breast Cancer ICYMI
Genentech Appeals to FDAs Regulatory Flexibility on Avastin
Breast Cancer ICYMI

Related Articles